Evaluation of Patient-Reported Outcomes with Etanercept in Moderate to Severe Plaque Psoriasis Patients After Therapy With Apremilast

April 2020 | Volume 19 | Issue 4 | Original Article | 378 | Copyright © April 2020


Published online March 6, 2020

Jerry Bagel , Bradley S. Stolshek , Yue Yang , Gregory Kricorian , Leon Kircik

aPsoriasis Treatment Center of Central New Jersey, East Windsor, NJ bAmgen Inc., Thousand Oaks, CA cIcahn School of Medicine, Mount Sinai, New York, NY; Indiana Medical Center, Indianapolis, IN; Physicians Skin Care, PLLC; DermResearch, PLLC, Louisville, KY

RESULTS

Patient Characteristics
A total of 80 patients (all received ETN) enrolled in this study; 60 due to apremilast efficacy failure (primary [n = 45] or secondary [n = 15]) and 20 because of apremilast intolerability (Table 1). Sixty-six patients (82.5%) completed the study, with 14 patients (17.5%) discontinuing. Overall, 41% of patients were female and 75% Caucasian; mean (SD) age was 50 (15) years and BMI was 30 (6). Mean (min – max) duration of psoriasis was 16 (1 – 62) years.

Efficacy
At week 12, 54 (70.1%), 32 (41.6%), and 10 (13.0%) of patients achieved PASI 50, PASI 75, and PASI 90, respectively. By week 24, 48 (62.3%), 35 (45.5%), and 17 (22.1%) of patients achieved PASI 50, PASI 75, and PASI 90, respectively.

DLQI and Satisfaction Scores
Among patients who achieved PASI 50, PASI 75, and PASI 90, 69.2%, 67.7%, and 90.0%, respectively, were DLQI responders at week 12 and 68.1%, 77.1%, and 82.4%, respectively, were DLQI responders at week 24 (Table 2). Among patients who achieved PASI 50, PASI 75, and PASI 90, 78.9%, 80.7%, and 100.0%, respectively, at week 12 and 77%, 86%, and 88%, respectively, at week 24 reported being “very satisfied” or “satisfied” with treatment (Table 2).

PSI Scores
Among patients who achieved PASI 50, PASI 75, and PASI 90 at week 12, baseline PSI total scores mean (SD) percent were 15.8% (6.3), 15.3% (6.8), and 14.8% (6.3), respectively. PSI total score mean (SD) percent improvement at week 12 was 45.1% (39.0), 57.0% (30.1), 67.2% (23.7), and 83.1% (18.3) in the overall study population and patients who achieved PASI 50, 75, and 90, respectively (Figure 1). At week 24, percent improvement was





<img